First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 36, Pages 4141-4148
Publisher
American Society of Clinical Oncology (ASCO)
Online
2014-11-18
DOI
10.1200/jco.2013.55.0376
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
- (2013) Teresa Coelho et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
- (2013) Josep Tabernero et al. Cancer Discovery
- Depletion of protein kinase N3 (PKN3) impairs actin and adherens junctions dynamics and attenuates endothelial cell activation
- (2012) Kristin Möpert et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
- (2011) Janos Szebeni et al. ADVANCED DRUG DELIVERY REVIEWS
- Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer
- (2011) Armelle Guelte et al. BIOLOGY OF THE CELL
- The interaction of PKN3 with RhoC promotes malignant growth
- (2011) Keziban Unsal-Kacmaz et al. Molecular Oncology
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?
- (2011) Katrien De Bock et al. Nature Reviews Clinical Oncology
- A Perspective on Cancer Cell Metastasis
- (2011) C. L. Chaffer et al. SCIENCE
- Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
- (2010) A. Santel et al. CLINICAL CANCER RESEARCH
- 556 Therapeutic siRNA delivery against PKN3 improves the antineoplastic efficacy of gemcitabine in an orthotopic pancreatic cancer model
- (2010) O. Stoeltzing et al. EJC SUPPLEMENTS
- Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
- (2010) Christophe Le Tourneau et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA interference for therapy in the vascular endothelium
- (2010) Jörg Kaufmann et al. MICROVASCULAR RESEARCH
- Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
- (2008) M. Aleku et al. CANCER RESEARCH
- The role of adherens junctions and VE-cadherin in the control of vascular permeability
- (2008) E. Dejana et al. JOURNAL OF CELL SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started